血浆syndecan-1与急诊科脓毒症患者的液体需求及临床结局相关
该研究为急诊液体复苏随机试验的事后分析,纳入95例脓毒症诱导低灌注且测过基线syndecan-1的成人。基线及6小时syndecan-1中位数均为207 ng/ml,与基线SOFA评分、24/72小时后续液体量、脓毒性休克诊断、最大血管加压药剂量及肾脏替代治疗需求相关;6小时较高syndecan-1与较高90天死亡率相关。提示syndecan-1或可辅助急诊脓毒症风险分层。
要点
- 急诊脓毒症诱导低灌注成人中,基线syndecan-1中位数207(IQR 135-438)ng/ml,6小时中位数207(IQR 128-490)ng/ml。
- 基线syndecan-1与基线SOFA评分相关(ρ=0.35,p<0.001),水平越高器官衰竭越重。
- 基线及6小时syndecan-1均与24和72小时后续液体量、脓毒性休克诊断、最大血管加压药剂量及肾脏替代治疗需求相关(p<0.05)。
- 6小时syndecan-1较高与较高90天死亡率相关(p=0.03)。
- 该标志物目前仅显示关联,不能替代临床决策,需前瞻性验证。
适用人群与场景
- 急诊科成人脓毒症诱导低灌注患者,且已测量基线syndecan-1水平者。
- 研究在 urban 1500-bed 三级医疗中心急诊科进行,为随机液体复苏试验的事后分析。
诊断标准与关键阈值
- 脓毒症诱导低灌注诊断标准原文未详述。
- 基线SOFA评分用于评估器官衰竭,syndecan-1与其相关(ρ=0.35,p<0.001)。
- 脓毒性休克诊断、最大血管加压药剂量及肾脏替代治疗需求为临床结局指标。
处置流程与药物剂量
- 原文未提及基于syndecan-1的具体治疗流程或药物剂量调整。
红旗征与不能漏的情况
- 原文未提及需要立刻处理或不能漏诊的具体红旗征及处理。
研究设计与关键结果
- 研究类型:随机试验的事后分析;样本量95例成人;单中心( urban 1500-bed 三级医疗中心急诊科)。
- 人群:脓毒症诱导低灌注且测量基线syndecan-1的成人。
- 干预与对照:原文未详述随机试验的干预与对照分组。
- 主要终点结果:基线syndecan-1与基线SOFA评分相关(ρ=0.35,p<0.001);T0和T6 syndecan-1与24和72小时后续液体量、脓毒性休克诊断、最大血管加压药剂量及肾脏替代治疗需求相关(p<0.05)。
- 关键次要终点:6小时较高syndecan-1与较高90天死亡率相关(p=0.03)。
- 不良事件:原文未提及。
证据类型、等级与局限
- 证据类型:随机对照试验的事后分析(研究论文)。
- 证据等级或推荐强度:原文未提及。
- 局限:事后分析、单中心、样本量小(95例)、观察性关联不能推断因果。
对床旁实践的改变
- 该内容提示急诊脓毒症患者可考虑检测syndecan-1以辅助风险分层,但原文未给出阈值或治疗调整方案。
- 适用人群:急诊脓毒症诱导低灌注成人;不适用人群及排除标准原文未提及。
- 常见陷阱:不能将关联性结果误读为因果或决策阈值,syndecan-1不能替代SOFA评分等临床评估。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Degradation of the endothelial glycocalyx is recognized as a major part of the pathophysiology of sepsis. Previous clinical studies, mostly conducted in intensive care settings, showed associations between glycocalyx shedding and clinical outcomes. We aimed to explore the association of plasma syndecan-1, a marker of glycocalyx degradation, with the subsequent fluid requirements and clinical outcomes of emergency department patients with sepsis.
METHODS: This was a post hoc analysis of a randomized trial of fluid resuscitation in the emergency department. The study was conducted in the emergency department of an urban 1500-bed tertiary care center. The data of 95 adults who were diagnosed with sepsis-induced hypoperfusion and had undergone baseline syndecan-1 measurement were included. The syndecan-1 levels at baseline (T0) and hour 6 (T6) were studied to characterize their association with clinical outcomes, including subsequent fluid administration, organ failure outcomes and mortality.
RESULTS: The median syndecan-1 levels at T0 and T6 were 207 (IQR 135-438) and 207 (IQR 128-490) ng/ml, respectively. Syndecan-1 levels at T0 were correlated with baseline sequential organ failure assessment (SOFA) score (ρ = 0.35, p < 0.001). Syndecan-1 levels at both T0 and T6 were correlated with subsequent fluid administration over 24 and 72 h and associated with the diagnosis of septic shock, the maximum dose of vasopressors and the need for renal replacement therapy (p < 0.05). Higher syndecan-1 levels at T6 were associated with higher 90-day mortality (p = 0.03).
CONCLUSIONS: In the emergency department, syndecan-1 levels were associated with fluid requirements, sepsis severity, organ dysfunction, and mortality.
参考来源
- Saoraya J, Wongsamita L, Srisawat N, et al. Plasma syndecan-1 is associated with fluid requirements and clinical outcomes in emergency department patients with sepsis. Am J Emerg Med. 2021. PMID: 33493833. doi:10.1016/j.ajem.2021.01.019
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。